Cited by 326Coenzyme Q10 studies and effectsParkinson's Disease Mechanisms and TreatmentsMitochondrial Function and Pathology

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects

Shults, Clifford W., Haas, Richard H., Passov, David, Beal, M. Flint·1997·Annals of Neurology

DOI 10.1002/ana.410420221

Open this paper in CoChat — free account

Abstract

The activities of complex I and complex II/III in platelet mitochondria are reduced in patients with early, untreated Parkinson's disease. Coenzyme Q 10 is the electron acceptor for complex I and complex II. We found that the level of coenzyme Q 10 was significantly lower in mitochondria from parkinsonian patients than in mitochondria from age‐ and sex‐matched control subjects and that the levels of coenzyme Q 10 and the activities of complex I and complex II/III were significantly correlated.

Integrity signals

Registry

Crossref · 10.1002/ana.410420221

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Biochemical, physiological and medical aspects of ubiquinone function
Ernster, L., & Dallner, G. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00028-3 · Cited by 1,246
Abnormalities of the electron transport chain in idiopathic parkinson's disease
Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Oxygen radicals and the nervous system
Halliwell, B. B., & Gutteridge, J. M. C. (1985) · Trends in Neurosciences · doi:10.1016/0166-2236(85)90010-4 · Cited by 823
Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease
Schapira, A. H. V., Mann, V. M., Cooper, J. A. D., Dexter, D. T., Daniel, S. E., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673
Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease
Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
Self-citation
Lovastatin decreases coenzyme Q levels in humans.
Folkers, K., Langsjoen, P. H., Willis, R. A., Richardson, P. C., Xia, L., Ye, C. Q., & Tamagawa, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.22.8931 · Cited by 426
Platelet mitochondria function in Parkinson's disease
Krige, D., Carroll, M. T., Cooper, J. A. D., MARSDEN, C. D., & Schapira, A. H. V. (1992) · Annals of Neurology · doi:10.1002/ana.410320612 · Cited by 358
Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes
Benecke, R., Strumper, P., & Weiss, H. (1993) · Brain · doi:10.1093/brain/116.6.1451 · Cited by 220

Show all 15 references

Research works printed but not linked: 1

Gotz ME, 1996, Platelet coenzyme Q10 in Parkinson's disease, Mov Disord, 11, 127

Sorted by citations

The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Role of Free Radicals in the Neurodegenerative Diseases: Therapeutic Implications for Antioxidant Treatment
Halliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Metabolism and function of coenzyme Q
Turunen, M., Olsson, J., & Dallner, G. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2003.11.012 · Cited by 1,026
International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
Fox, S. H., Katzenschlager, R., Lim, S., Barton, B. R., de Bie, R. M. A., Seppi, K., Coelho, M. M., & Sampaio, C. (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,009
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Self-citation
Expression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
Idiopathic hyposmia as a preclinical sign of Parkinson's disease
Ponsen, M. M., Stoffers, D., Booij, J., van Eck‐Smit, B. L. F., Wolters, E. C., & Berendse, H. W. (2004) · Annals of Neurology · doi:10.1002/ana.20160 · Cited by 758
Experimental models of Parkinson's disease
Beal, M. F. (2001) · Nature reviews. Neuroscience · doi:10.1038/35072550 · Cited by 645
Self-citation
A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease
Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Coenzyme Q 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects
Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557
Self-citation
Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease
Beal, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 529
Self-citation
Oxidative Stress in Parkinson's Disease
Zhou, C. H., Huang, Y., & Przedborski, S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.023 · Cited by 460
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 410
Self-citation
Mitochondria in Neurodegeneration: Acute Ischemia and Chronic Neurodegenerative Diseases
Fiskum, G. M., Murphy, A. N., & Beal, M. F. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199904000-00001 · Cited by 354
Self-citation
The Role of Oxidative Stress in Parkinson’s Disease
Chang, K., & Chen, C. (2020) · Antioxidants · doi:10.3390/antiox9070597 · Cited by 369
Melatonin and mitochondrial function
León, J., Acuña-Castroviejo, D., Sainz, R. M., Mayo, J. C., Tan, D., & Reiter, R. J. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.03.003 · Cited by 331
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 296
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294
Self-citation
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.1.139 · Cited by 275
Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice
Beal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256
Self-citation
Mitochondrial Mechanisms of Neural Cell Death and Neuroprotective Interventions in Parkinson's Disease
Fiskum, G. M., Starkov, A. A., Polster, B. M., & Chinopoulos, C. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07469.x · Cited by 252
Antioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 255
Calcium homeostasis, selective vulnerability and Parkinson's disease
Chan, C. S., Gertler, T. S., & Surmeier, D. J. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.01.006 · Cited by 245
The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease
Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., & Schumacker, P. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.045 · Cited by 236
Bioenergetic approaches for neuroprotection in Parkinson's disease
Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236
Self-citation
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III
Kaufmann, P., Thompson, J. L. P., Levy, G., Buchsbaum, R., Shefner, J. M., Krivickas, L. S., Katz, J., Rollins, Y. D., Barohn, R. J., Jackson, C. E., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21743 · Cited by 236
Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases
Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Beal, M. F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 237
Self-citation
Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease
Surmeier, D. J., Guzmán, J. N., & Sánchez-Padilla, J. (2010) · Cell Calcium · doi:10.1016/j.ceca.2009.12.003 · Cited by 224
A randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson disease
The NINDS NET-PD Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000250355.28474.8e · Cited by 220
Glutathione and Parkinson's disease: Is this the elephant in the room?
Zeevalk, G. D., Razmpour, R., & Bernard, L. P. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.01.017 · Cited by 217
Suboptimal medication adherence in Parkinson's disease
Grosset, K. A., Bone, I., & Grosset, D. G. (2005) · Movement Disorders · doi:10.1002/mds.20602 · Cited by 206
Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease
Müller, T. H., Büttner, T., Gholipour, A.-F., & Kuhn, W. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00185-x · Cited by 203
Coenzyme Q10 Deficiency and Response to Supplementation in Pediatric and Adolescent Migraine
Hershey, A. D., Powers, S. W., Vockell, A.-L. B., LeCates, S. L., Ellinor, P. L., Segers, A. M., Burdine, D., Manning, P., & Kabbouche, M. A. (2007) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2007.00652.x · Cited by 197
Progress in Parkinson's disease—Where do we stand?
Toulouse, A., & Sullivan, A. M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.003 · Cited by 197
Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model
Ghosh, A., Chandran, K., Kalivendi, S. V., Joseph, J., Antholine, W. E., Hillard, C. J., Kanthasamy, A., Kanthasamy, A. G., & Kalyanaraman, B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.08.028 · Cited by 194
A53T Human α-Synuclein Overexpression in Transgenic Mice Induces Pervasive Mitochondria Macroautophagy Defects Preceding Dopamine Neuron Degeneration
Chen, L., Xie, Z., Turkson, S., & Zhuang, X. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0089-14.2015 · Cited by 194
Coenzyme Q10 effects in neurodegenerative disease
Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 189
Safety assessment of coenzyme Q 10 (CoQ 10 )
Hidaka, T., Fujii, K., Funahashi, I., Fukutomi, N., & Hosoe, K. (2008) · BioFactors · doi:10.1002/biof.5520320124 · Cited by 187
Mitophagy and Oxidative Stress: The Role of Aging
Gaetano, A. D., Gibellini, L., Zanini, G., Nasi, M., Cossarizza, A., & Pinti, M. (2021) · Antioxidants · doi:10.3390/antiox10050794 · Cited by 196
Neuroprotective effects of the antiparkinson drug Mucuna pruriens
Manyam, B. V., Dhanasekaran, M., & Hare, T. A. (2004) · Phytotherapy Research · doi:10.1002/ptr.1514 · Cited by 185
Coenzyme Q10 Inhibits Glutamate Excitotoxicity and Oxidative Stress–Mediated Mitochondrial Alteration in a Mouse Model of Glaucoma
Lee, D.-W., Shim, M. S., Keun-young Kim, A., Noh, Y. H., Kim, H., Kim, S. Y., Weinreb, R. N., & Ju, W. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12564 · Cited by 182
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses
Morris, G., Berk, M., Walder, K. R., & Maes, M. H. J. (2015) · BMC Medicine · doi:10.1186/s12916-014-0259-2 · Cited by 187
Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease
Chen, J. J., & Swope, D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005277935 · Cited by 179
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
Schapira, A. H. V., & Obeso, J. A. (2006) · Annals of Neurology · doi:10.1002/ana.20789 · Cited by 177
AMP Kinase Activation Mitigates Dopaminergic Dysfunction and Mitochondrial Abnormalities inDrosophilaModels of Parkinson's Disease
Ng, C.-H., Guan, M. S. H., Koh, C., Ouyang, X., Yu, F., Tan, E., O’Neill, S., Zhang, X., Chung, J., & Lim, K. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0499-12.2012 · Cited by 178
Mitochondrial Dysfunction in Parkinson's Disease
Keane, P. C., Kurzawa‐Akanbi, M., Blain, P. G., & Morris, C. M. (2011) · Parkinson s Disease · doi:10.4061/2011/716871 · Cited by 182
Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10
Moon, Y., Lee, K. H., Park, J., Geum, D., & Kim, K. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03112.x · Cited by 174
Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease
Carboni, E., & Lingor, P. (2015) · Metallomics · doi:10.1039/c4mt00339j · Cited by 170
Metal‐Catalyzed Disruption of Membrane Protein and Lipid Signaling in the Pathogenesis of Neurodegenerative Disorders
Mattson, M. P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.004 · Cited by 162
Therapeutic effects of coenzyme Q 10 (CoQ 10 ) and reduced CoQ 10 in the MPTP model of Parkinsonism
Cléren, C., Yang, L., Lorenzo, B. J., Calingasan, N. Y., Schomer, A. C., Sireci, A. N., Wille, E. J., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05097.x · Cited by 158
Self-citation
Coenzyme Q 10 as a Possible Treatment for Neurodegenerative Diseases
Beal, M. F. (2002) · Free Radical Research · doi:10.1080/10715760290021315 · Cited by 160
Self-citation
Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction
Park, J.-S., Koentjoro, B., Veivers, D., Mackay‐Sim, A., & Sue, C. M. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt623 · Cited by 160
Qigong exercise for the symptoms of Parkinson's disease: A randomized, controlled pilot study
Schmitz‐Hübsch, T., Pyfer, D., Kielwein, K., Fimmers, R., Klockgether, T., & Wüllner, U. (2005) · Movement Disorders · doi:10.1002/mds.20705 · Cited by 155
Coenzyme Q10 Therapy
Garrido‐Maraver, J., Cordero, M. D., Oropesa-Ávila, M., Fernández-Vega, A., de la Mata, M., Pavón, A. D., de Miguel, M., Calero, C. P., Paz, M. V., Cotán, D., et al. (2014) · Molecular Syndromology · doi:10.1159/000360101 · Cited by 161
Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation
Cárdenes, N., Corey, C. G., Geary, L., Jain, S., Zharikov, S. I., Barge, S., Novelli, E. M., & Shiva, S. (2014) · Blood · doi:10.1182/blood-2013-09-529420 · Cited by 152
Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease
Faust, K., Gehrke, S., Yang, Y., Yang, L., Beal, M. F., & Lu, B. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-109 · Cited by 151
Self-citation
Feeding mitochondria: Potential role of nutritional components to improve critical illness convalescence
Wesselink, E., Koekkoek, W. A. C., Grefte, S., Witkamp, R. F., & van Zanten, A. R. H. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.08.032 · Cited by 149
Progress on the Mitochondrial Permeability Transition Pore: Regulation by Complex I and Ubiquinone Analogs
Fontaine, E. M., & Bernardi, P. (1999) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1005475802350 · Cited by 149
Inhibition of oxidative stress by coenzyme Q10 increases mitochondrial mass and improves bioenergetic function in optic nerve head astrocytes
Noh, Y. H., Kim, K., Shim, M. S., Choi, S.-H., Choi, S., Ellisman, M. H., Weinreb, R. N., Perkins, G. A., & Ju, W.-K. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.341 · Cited by 146
Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease
Sohmiya, M., Tanaka, M., Wei Tak, N., Yanagisawa, M., Tanino, Y., Suzuki, Y., Okamoto, K., & Yamamoto, Y. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.007 · Cited by 143
The Origins of Oxidant Stress in Parkinson's Disease and Therapeutic Strategies
Surmeier, D. J., Guzmán, J. N., Sánchez-Padilla, J., & Goldberg, J. A. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3521 · Cited by 142
Therapeutic prospects for Parkinson disease
Olanow, C. W., & Schapira, A. H. V. (2013) · Annals of Neurology · doi:10.1002/ana.24011 · Cited by 145
The Promise of Neuroprotective Agents in Parkinson?s Disease
Seidl, S. E., & Potashkin, J. A. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00068 · Cited by 145
Review: Familial Parkinson's disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease
Schiesling, C., Kieper, N., Seidel, K., & Krüger, R. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00952.x · Cited by 143
A randomized trial of coenzyme Q 10 in mitochondrial disorders
Glover, E. I., Martin, J. C., Maher, A. C., Thornhill, R. E., Moran, G. R., & Tarnopolsky, M. A. (2010) · Muscle & Nerve · doi:10.1002/mus.21758 · Cited by 137
Oxidative Stress Involvement in α -Synuclein Oligomerization in Parkinson's Disease Cybrids
Esteves, A. R., Arduíno, D. M., Swerdlow, R. H., Oliveira, C. R., & Cardoso, S. M. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2247 · Cited by 137
Mitochondrial alterations in Parkinson’s disease: new clues
Vila, M., Ramonet, D., & Perier, C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05604.x · Cited by 131
Levels of reduced and oxidized coenzymeQ-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process
Isobe, C., Abe, T., & Terayama, Y. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.065 · Cited by 130
Is coenzyme Q a key factor in aging?
López‐Lluch, G., Rodríguez‐Aguilera, J. C., Santos‐Ocaña, C., & Navas, P. (2010) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2010.02.003 · Cited by 140
Mitochondrial DNA analysis: polymorphisms and pathogenicity
Chinnery, P. F., Howell, N., Andrews, R. M., & Turnbull, D. M. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.7.505 · Cited by 129
Control of Reactive Oxygen Species for the Prevention of Parkinson’s Disease: The Possible Application of Flavonoids
Kim, T. Y., Leem, E., Lee, J. M., & Kim, S. R. (2020) · Antioxidants · doi:10.3390/antiox9070583 · Cited by 135
An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition
Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
Tissue transglutaminase catalyzes the formation of alpha‐synuclein crosslinks in Parkinson's disease
Andringa, G., Lam, K., Chegary, M., Wang, X., Chase, T. N., & Bennett, M. C. (2004) · The FASEB Journal · doi:10.1096/fj.03-0829fje · Cited by 123
Mitochondrial dysfunction and amyotrophic lateral sclerosis
Hervías, I., Beal, M. F., & Manfredi, G. (2005) · Muscle & Nerve · doi:10.1002/mus.20489 · Cited by 122
Self-citation
Physiological Phenotype and Vulnerability in Parkinson's DiseasePreprint
Surmeier, D. J., Guzmán, J. N., Sánchez, J. A., & Schumacker, P. T. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009290 · Cited by 123
Coenzyme Q Induces Nigral Mitochondrial Uncoupling and Prevents Dopamine Cell Loss in a Primate Model of Parkinson’s Disease
Horváth, T. L., Diano, S., Léránth, C., García‐Segura, L. M., Cowley, M. A., Shanabrough, M., Elsworth, J. D., Sótonyi, P., Roth, R. H., Dietrich, E. H., et al. (2003) · Endocrinology · doi:10.1210/en.2003-0163 · Cited by 117
Coenzyme Q10administration and its potential for treatment of neurodegenerative diseases
Beal, M. F. (1999) · BioFactors · doi:10.1002/biof.5520090222 · Cited by 111
Self-citation
Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.
Kidd, P. M. (2000) · PubMed · Cited by 110
Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View
Filograna, R., Beltramini, M., Bubacco, L., & Bisaglia, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030102718 · Cited by 110
The Roles of Coenzyme Q in Disease: Direct and Indirect Involvement in Cellular Functions
Pallotti, F., Bergamini, C., Lamperti, C., & Fato, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010128 · Cited by 109
Genetic Insights into Sporadic Parkinson's Disease Pathogenesis
Chai, C., & Lim, K. (2014) · Current Genomics · doi:10.2174/1389202914666131210195808 · Cited by 113
The Centrality of Mitochondria in the Pathogenesis and Treatment of Parkinson's Disease
Camilleri, A., & Vassallo, N. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12264 · Cited by 106
Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease
Beal, M. F. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70812-0 · Cited by 104
Self-citation
Mitochondrial dysfunction and Parkinson disease: a Parkin–AMPK alliance in neuroprotection
Hang, L., Thundyil, J., & Lim, K. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12820 · Cited by 103
Clinical measures of progression in Parkinson's disease
Poewe, W. H. (2009) · Movement Disorders · doi:10.1002/mds.22600 · Cited by 98
Coenzyme Q10:A Review of Its Promise as a Neuroprotectant
Young, A. J., Johnson, S., Steffens, D. C., & Doraiswamy, P. M. (2007) · CNS Spectrums · doi:10.1017/s1092852900020538 · Cited by 100
Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications
Morris, G., Anderson, G., Berk, M., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8477-8 · Cited by 96
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine‐associated diseases
Gluck, M. R., & Zeevalk, G. D. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02747.x · Cited by 96
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging
Shrader, W. D., Amagata, A., Barnes, A. J., Enns, G. M., Hinman, A., Jankowski, O. D., Kheifets, V., Komatsuzaki, R., Lee, E., Mollard, P., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.085 · Cited by 98
Glutamate and Mitochondria: Two Prominent Players in the Oxidative Stress-Induced Neurodegeneration
Cassano, T., Pace, L., Bedse, G., Lavecchia, A. M., Marco, F. D., Gaetani, S., & Serviddio, G. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151218132725 · Cited by 96
High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease
Jia, H., Li, X., Gao, H., Feng, Z., Li, X., Zhao, L., Jia, X., Zhang, H., & Liu, J. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21650 · Cited by 98
Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain
Manzar, H., Abdulhussein, D., Yap, T. E., & Cordeiro, M. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239299 · Cited by 97
Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease
Yoritaka, A., Kawajiri, S., Yamamoto, Y., Nakahara, T., Ando, M., Hashimoto, K., Nagase, M., Saito, Y., & Hattori, N. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.022 · Cited by 94
Medicine‐taking behavior: Implications of suboptimal compliance in Parkinson's disease
Grosset, K. A., Reid, J. L., & Grosset, D. G. (2005) · Movement Disorders · doi:10.1002/mds.20525 · Cited by 92
Altered redox state of platelet coenzyme Q 10 in Parkinson's disease
Götz, M. E., Gerstner, A., Harth, R., Dirr, A., Janetzky, B., Kuhn, W., Riederer, P., & Gerlach, M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050003 · Cited by 93
Coenzyme Q10: From bench to clinic in aging diseases, a translational review
Gutierrez-Mariscal, F. M., Yubero-Serrano, E. M., Villalba, J. M., & Lopez-Miranda, J. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1442316 · Cited by 92
A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease
Shults, C. W., Haas, R., & Beal, M. F. (1999) · BioFactors · doi:10.1002/biof.5520090223 · Cited by 91
Self-citation
Nrf2 Pathway in Age-Related Neurological Disorders: Insights into MicroRNAs
Paladino, S., Conte, A., Caggiano, R., Pierantoni, G. M., & Faraonio, R. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491465 · Cited by 92
Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects
The Huntington Study Group Pre2CARE Investigators (2010) · Movement Disorders · doi:10.1002/mds.22408 · Cited by 91
Nutrients to Improve Mitochondrial Function to Reduce Brain Energy Deficit and Oxidative Stress in Migraine
Fila, M., Chojnacki, C. J., Chojnacki, J., & Błasiak, J. (2021) · Nutrients · doi:10.3390/nu13124433 · Cited by 95

Authors: Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F.
Affiliations: United States Department of Veterans Affairs (US)
University of California San Diego (US)
Massachusetts General Hospital (US)
Corresponding author: Shults, Clifford W.
ORCID: Haas, Richard H.
Venue: Annals of Neurology
Publisher: Wiley
Published: 1997-08
Volume: 42
Issue: 2
Pages: 261-264
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410420221
OpenAlex: W2084464741
Cited by: 326
References: 15
Citations by year: 2026: 3 · 2025: 3 · 2024: 6 · 2023: 8 · 2022: 12 · 2021: 14 · 2020: 10 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 6 · 2015: 11 · 2014: 16 · 2013: 14 · 2012: 11
FWCI: 2.00
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2625 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ns032365-03, 5r01ns029504-03)
U.S. Public Health Service (P01 12992)
National Institute of Neurological Disorders and Stroke (R01 NS32365, R01 NS29504)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords: coenzyme Q10, Parkinson's disease, mitochondrial complex I, platelet mitochondria, mitochondrial electron transport chain, mitochondrial dysfunction
MeSH terms: Blood Platelets, Coenzymes, Female, Humans, Male, Mitochondria, Multienzyme Complexes, Oxidoreductases, Parkinson Disease, Reference Values, Succinate Dehydrogenase, Electron Transport Complex III, Ubiquinone, NAD(P)H Dehydrogenase (Quinone), Electron Transport Complex II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks